New shot targets tough cancers: early trial seeks 150 patients
NCT ID NCT07390838
First seen Feb 05, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This early-stage study tests a new drug called SH009 in about 150 people with advanced solid tumors (like liver, lung, or breast cancer) that have not responded to standard treatments. The main goal is to see if the drug is safe and can shrink tumors. Researchers will also measure how long any benefits last and how the drug behaves in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Gaobo Cancer Hospital
RECRUITINGShanghai, China
Conditions
Explore the condition pages connected to this study.